BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sampani E, Sarafidis P, Dimitriadis C, Kasimatis E, Daikidou D, Bantis K, Papanikolaou A, Papagianni A. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. BMC Nephrol 2020;21:276. [PMID: 32669085 DOI: 10.1186/s12882-020-01930-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Sitina M, Lukes M, Sra V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis.. [DOI: 10.21203/rs.3.rs-2308651/v1] [Reference Citation Analysis]
2 Mosallanejad S, Mahmoodi M, Tavakkoli H, Khosravi A, Salarkia E, Keyhani A, Dabiri S, Gozashti MH, Pardakhty A, Khodabandehloo H, Pourghadamyari H. Empagliflozin induces apoptotic-signaling pathway in embryonic vasculature: In vivo and in silico approaches via chick’s yolk sac membrane model. Front Pharmacol 2022;13:970402. [DOI: 10.3389/fphar.2022.970402] [Reference Citation Analysis]
3 Pathak BD, Dhakal B, Bhattarai AM, Regmi BU, Mandal SK, Panta PR, Khadka S, Simkhada N. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. Annals of Medicine and Surgery 2022;79:104118. [DOI: 10.1016/j.amsu.2022.104118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Aung NL, Vakani V, Wassel M. A Case of Hyperglycemic Ketoacidosis in a Patient Without Diabetes. Cureus 2022. [DOI: 10.7759/cureus.24560] [Reference Citation Analysis]
5 Kietaibl A, Fasching P, Glaser K, Petter-puchner AH. New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature. Front Surg 2022;9:828649. [DOI: 10.3389/fsurg.2022.828649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Alhemeiri M, Alseddeeqi E, Isozaki O. Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor. Case Reports in Endocrinology 2022;2022:1-4. [DOI: 10.1155/2022/4101975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yii ESS, Azli AW, Sitaram PN. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report. J Med Case Rep 2022;16:17. [PMID: 34983625 DOI: 10.1186/s13256-021-03232-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ata F, Yousaf Z, Khan AA, Razok A, Akram J, Ali EAH, Abdalhadi A, Ibrahim DA, Al Mohanadi DHSH, Danjuma MI. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep 2021;11:10293. [PMID: 33986421 DOI: 10.1038/s41598-021-89752-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
9 Somagutta MR, Agadi K, Hange N, Jain MS, Batti E, Emuze BO, Amos-Arowoshegbe EO, Popescu S, Hanan S, Kumar VR, Pormento K. Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers. Cureus 2021;13:e13665. [PMID: 33824816 DOI: 10.7759/cureus.13665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
10 Dass B, Beck A, Holmes C, Morton G. Euglycemic DKA (euDKA) as a presentation of COVID-19. Clin Case Rep 2020. [PMID: 33362928 DOI: 10.1002/ccr3.3540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Empagliflozin. Reactions Weekly 2020;1819:112-112. [DOI: 10.1007/s40278-020-82655-y] [Reference Citation Analysis]